What Has Been the Growth of the Inherited Retinal Disease Market So Far?
The inherited retinal disease market has seen considerable growth due to a variety of factors.
• The market size for inherited retinal disease has seen a significant increase in recent times. Anticipated to rise from $11.56 billion in 2024 to $12.58 billion in 2025, the compound annual growth rate (CAGR) stands at 8.8%.
The impressive growth during the historic period is attributed to factors such as the utilization of gene therapy, regulatory incentives, increased patient registries, a surge in clinical trials, and the growth of patient-oriented solutions.
What Is the Forecasted Market Size and Growth Rate for The Inherited Retinal Disease Market?
The inherited retinal disease market is expected to maintain its strong growth trajectory in upcoming years.
• The market for inherited retinal diseases is predicted to witness substantial expansion in the upcoming years. It is projected to escalate to $17.42 billion by 2029, rising at an 8.5% Compound Annual Growth Rate (CAGR). The surge in this period can be explained by factors such as the growing utilization of CRISPR technology, the advent of individualized treatment strategies, emphasis on regenerative medicine, increased patient advocacy initiatives, and a heightened ambition to enhance patients' living standards. Prominent trends for the predicted period consist of progress in optogenetics technology, creation of artificial retina implants, expansion in digital health landscapes, application of artificial intelligence in disease representation, and the employment of AI in determining the appropriate treatment plans.
Which Key Drivers Are Propelling Th Inherited Retinal Disease Market's Growth?
The inherited retinal disease market is projected to expand with the rise in occurrences of macular degeneration. This age-related condition affects the macula in the eye, causing loss of central vision and hindrances in simple activities like reading and identifying faces. The increasing number of cases can be attributed to aging, increased longevity, and lifestyle factors such as smoking and lack of nutritional diet, which raises the risks. Treatments for inherited retinal diseases aid patients with macular degeneration by focusing on the fundamental genetic reasons for retinal degeneration. The market offers therapies to slow down the progress of the disease, bring back lost vision and even prevent further harm to the retina, ultimately enhancing the vision outcomes and life quality of individuals suffering from age-related or inherited macular degeneration. For example, the Canadian Ophthalmological Society, a non-profit organization based in Canada, reported in February 2024 that 2.5 million Canadians aged over 55 lose their vision due to age-related macular degeneration (AMD). Consequently, the increasing cases of macular degeneration play a significant role in driving the growth of the inherited retinal disease market.
What Are The Main Segments Of The Global Inherited Retinal Disease Market?
The inherited retinal disease market covered in this report is segmented –
1) By Type: Diagnosis, Therapy
2) By Disease Type: Retinitis Pigmentosa, Choroideremia, Stargardt Disease, Cone-rode Dystrophy, Leber Congenital Amaurosis, Other Diseases
3) By Distribution Channel: Retail Sales, Direct Tender
4) By End Users: Hospitals, Speciality Clinics, Ambulatory Surgical Centres, Home Healthcare, Other End Users
Subsegments,
1) By Diagnosis: Genetic Testing (Genetic Screening), Retinal Imaging (Fundus Photography, Optical Coherence Tomography (OCT)), Electrophysiological Testing (Electroretinography), Visual Field Testing, Fundus Autofluorescence Imaging
2) By Therapy: Gene Therapy, Stem Cell Therapy, Retinal Prosthesis (Artificial Retina), Pharmacological Therapy (Gene Editing, Retinal Drugs), Photoreceptor Rescue Therapy
Pre-Book The Inherited Retinal Disease Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Inherited Retinal Disease Market Landscape?
Key players in the inherited retinal diseases market concentrate on the advancement of groundbreaking therapies such as mutation-agnostic gene therapy. This method aims to provide comprehensive treatment options that tackle a more considerable span of genetic variations correlated with these diseases. Instead of concentrating on specific mutations, mutation-agnostic gene therapy targets broader genetic mechanisms or pathways, making it relevant for a multitude of genetic disorders. To cite an example, Nanoscope Therapeutics Inc, a biotechnology corporation based in the USA, reported positive outcomes from a clinical trial of its premier program, MCO-010, in March 2024. The trial showed that MCO-010 enhances vision for patients suffering from severe and permanent vision loss as a result of advanced retinitis pigmentosa, meeting its primary and crucial secondary endpoints with statistical significance, and without any severe adverse incidents.
Who Are the Key Players in the Inherited Retinal Disease Market?
Major companies operating in the inherited retinal disease market are include:
• Johnson & Johnson
• Novartis AG
• Astellas Pharma Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Invitae Corporation
• Spark Therapeutics
• Aldeyra Therapeutics
• Regenxbio Inc.
• IVERIC bio
• MeiraGTx Limited
• Ocugen Inc.
• Coave Therapeutics
• Bionic Vision Technologies
• GenSight Biologics SA
• LKC Technologies Inc.
• Sparing Vision
• ProQR Therapeutics NV
• Endogena Therapeutics
What Is The Most Dominant Region In The Inherited Retinal Disease Market?
North America was the largest region in the inherited retinal disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inherited retinal disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
